Access to more effective therapies in Non-Hodgkin Lymphoma

Impact: Health and wellbeing, Economic

Narrative

We were pivotal to the development of two novel therapies in Non-Hodgkin Lymphoma (NHL), increasing patient access to more effective, targeted drugs.

Brentuximab Vedotin in T cell NHL improved long-term survival in relapsed disease, was practice-changing and established a new standard of clinical care. Approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA), it was recommended in UK and US clinical guidelines.

Obinutuzumab, a treatment for B cell NHL and chronic lymphocytic leukaemia (CLL), was approved with chemotherapy in 2017 by the EMA and FDA for untreated advanced follicular lymphoma (FL). It brought the first change to standard of care for over 10 years, offering a more effective patient treatment.

Impact date1 Aug 2013 → 31 Dec 2020
Category of impactHealth and wellbeing, Economic
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre

Documents & Links

Related content